Faget Comments on Likely Effects of HHS Proposal to Curb Rebates
February 20, 2019
BioPharm Insight
Special Counsel Kyle Faget is quoted in a BioPharm Insight article, “Biosimilars, diabetes and HCV drug uptake expected to spike with HHS changes restricting safe harbor protection for PBMs and drug manufacturers, experts say,” about the expected impact of a new U.S. Department of Health and Human Services proposal to exclude rebates on prescription drugs from safe harbor protection under the anti-kickback statute.
Faget said an obstacle to automatic biosimilar uptake under the proposal may be that as opposed to generics, pharmacists cannot automatically switch out an originator for a biosimilar, unless interchangeability has been established by the biosimilar maker. She cited the example of Pfizer’s Ixifi, which can’t be substituted for Remicade by a pharmacist even if it’s cheaper. Remicade is approved to treat a number of indications, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and ankylosing spondylitis.
(Subscription Required)
Faget said an obstacle to automatic biosimilar uptake under the proposal may be that as opposed to generics, pharmacists cannot automatically switch out an originator for a biosimilar, unless interchangeability has been established by the biosimilar maker. She cited the example of Pfizer’s Ixifi, which can’t be substituted for Remicade by a pharmacist even if it’s cheaper. Remicade is approved to treat a number of indications, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and ankylosing spondylitis.
(Subscription Required)
People
Related News
December 3, 2025
In the News
Vanessa Miller Assesses Automotive Tariff Impact on Trucking Industry
Foley & Lardner LLP partner Vanessa Miller discussed the ongoing disruption in trucking demand resulting from recent automotive tariffs in the TruckingDive article, “Tariffs swing volumes up and down for auto haulers.”
November 28, 2025
In the News
Cassandra Aubert Assesses Circuit Split on SEC Disgorgement Authority
Foley & Lardner LLP associate Cassandra Aubert commented on the growing scrutiny around the U.S. Security and Exchange Commission's disgorgement authority in the Bloomberg Law's article, “SEC Power to Recoup Illegal Profits at Risk as Justices Eye Case."
November 25, 2025
In the News
Gregory Husisian Analyzes SCOTUS Tariff Case
Foley & Lardner LLP partner Gregory Husisian appeared in a SupplyChainBrain video interview to discuss the U.S. Supreme Court case on the Trump administration’s imposition of tariffs under the International Emergency Economic Powers Act (IEEPA) and options the administration can consider should the court strike them down.